Cargando…

Afatinib in combination with GEMOX chemotherapy as the adjuvant treatment in patients with ErbB pathway mutated, resectable gallbladder cancer: study protocol for a ctDNA-based, multicentre, open-label, randomised, controlled, phase II trial

INTRODUCTION: Gallbladder cancer (GBC) is an aggressive type of digestive system cancer with a dismal outcome. Given the lack of effective treatment options, the disease rapidly reoccurs and 5-year survival rate is <5%. Our team previously found that a significant percentage of GBC tissues harbou...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Mao, Zhao, Yuhao, Li, Yongsheng, Cui, Xuya, Liu, Fatao, Wu, Wenguang, Wang, Xu-An, Li, Maolan, Liu, Yun, Liu, Yingbin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9980349/
https://www.ncbi.nlm.nih.gov/pubmed/36854604
http://dx.doi.org/10.1136/bmjopen-2022-061892
_version_ 1784899896593088512
author Yang, Mao
Zhao, Yuhao
Li, Yongsheng
Cui, Xuya
Liu, Fatao
Wu, Wenguang
Wang, Xu-An
Li, Maolan
Liu, Yun
Liu, Yingbin
author_facet Yang, Mao
Zhao, Yuhao
Li, Yongsheng
Cui, Xuya
Liu, Fatao
Wu, Wenguang
Wang, Xu-An
Li, Maolan
Liu, Yun
Liu, Yingbin
author_sort Yang, Mao
collection PubMed
description INTRODUCTION: Gallbladder cancer (GBC) is an aggressive type of digestive system cancer with a dismal outcome. Given the lack of effective treatment options, the disease rapidly reoccurs and 5-year survival rate is <5%. Our team previously found that a significant percentage of GBC tissues harboured mutations of the ErbB-related pathway. Afatinib is a chemically synthesised drug specifically targeting the ErbB pathway mutations. However, its efficacy in the treatment of patients with GBC remains unknown. Circulating tumour DNA (ctDNA) refers to a proportion of cell-free DNA in the blood which is released by apoptotic and necrotic cells from tumours in situ, metastatic foci or circulating tumour cells. ctDNA-based liquid biopsy is a non-invasive pathological detection method that offers additional value to evaluate the therapeutic efficacy of antitumour drugs. METHODS AND ANALYSIS: We conduct a multicentre and randomised study on afatinib combined with gemcitabine and oxaliplatin (GEMOX) in patients with ErbB pathway mutated GBC. Clinical and biological evaluation involving ErbB pathway ctDNA detection will be made during the 3-year follow-up after participation. The primary objective of this clinical trial is to evaluate the clinical efficacy of afatinib. Disease-free survival is the primary end point and will be correlated with plasma ctDNA of patients in the treatment with afatinib. In addition, we will evaluate the sensitivity and specificity of plasma ctDNA for monitoring tumour recurrence and progression. Finally, we will assess the safety of afatinib by keeping an eye on the safety indicators. ETHICS AND DISSEMINATION: The study was approved by the medical-ethical review committee of Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine and Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine. The clinical trials results, even inconclusive, will be published in peer-reviewed journals. TRIAL REGISTRATION NUMBER: NCT04183712.
format Online
Article
Text
id pubmed-9980349
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-99803492023-03-03 Afatinib in combination with GEMOX chemotherapy as the adjuvant treatment in patients with ErbB pathway mutated, resectable gallbladder cancer: study protocol for a ctDNA-based, multicentre, open-label, randomised, controlled, phase II trial Yang, Mao Zhao, Yuhao Li, Yongsheng Cui, Xuya Liu, Fatao Wu, Wenguang Wang, Xu-An Li, Maolan Liu, Yun Liu, Yingbin BMJ Open Oncology INTRODUCTION: Gallbladder cancer (GBC) is an aggressive type of digestive system cancer with a dismal outcome. Given the lack of effective treatment options, the disease rapidly reoccurs and 5-year survival rate is <5%. Our team previously found that a significant percentage of GBC tissues harboured mutations of the ErbB-related pathway. Afatinib is a chemically synthesised drug specifically targeting the ErbB pathway mutations. However, its efficacy in the treatment of patients with GBC remains unknown. Circulating tumour DNA (ctDNA) refers to a proportion of cell-free DNA in the blood which is released by apoptotic and necrotic cells from tumours in situ, metastatic foci or circulating tumour cells. ctDNA-based liquid biopsy is a non-invasive pathological detection method that offers additional value to evaluate the therapeutic efficacy of antitumour drugs. METHODS AND ANALYSIS: We conduct a multicentre and randomised study on afatinib combined with gemcitabine and oxaliplatin (GEMOX) in patients with ErbB pathway mutated GBC. Clinical and biological evaluation involving ErbB pathway ctDNA detection will be made during the 3-year follow-up after participation. The primary objective of this clinical trial is to evaluate the clinical efficacy of afatinib. Disease-free survival is the primary end point and will be correlated with plasma ctDNA of patients in the treatment with afatinib. In addition, we will evaluate the sensitivity and specificity of plasma ctDNA for monitoring tumour recurrence and progression. Finally, we will assess the safety of afatinib by keeping an eye on the safety indicators. ETHICS AND DISSEMINATION: The study was approved by the medical-ethical review committee of Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine and Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine. The clinical trials results, even inconclusive, will be published in peer-reviewed journals. TRIAL REGISTRATION NUMBER: NCT04183712. BMJ Publishing Group 2023-02-28 /pmc/articles/PMC9980349/ /pubmed/36854604 http://dx.doi.org/10.1136/bmjopen-2022-061892 Text en © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Oncology
Yang, Mao
Zhao, Yuhao
Li, Yongsheng
Cui, Xuya
Liu, Fatao
Wu, Wenguang
Wang, Xu-An
Li, Maolan
Liu, Yun
Liu, Yingbin
Afatinib in combination with GEMOX chemotherapy as the adjuvant treatment in patients with ErbB pathway mutated, resectable gallbladder cancer: study protocol for a ctDNA-based, multicentre, open-label, randomised, controlled, phase II trial
title Afatinib in combination with GEMOX chemotherapy as the adjuvant treatment in patients with ErbB pathway mutated, resectable gallbladder cancer: study protocol for a ctDNA-based, multicentre, open-label, randomised, controlled, phase II trial
title_full Afatinib in combination with GEMOX chemotherapy as the adjuvant treatment in patients with ErbB pathway mutated, resectable gallbladder cancer: study protocol for a ctDNA-based, multicentre, open-label, randomised, controlled, phase II trial
title_fullStr Afatinib in combination with GEMOX chemotherapy as the adjuvant treatment in patients with ErbB pathway mutated, resectable gallbladder cancer: study protocol for a ctDNA-based, multicentre, open-label, randomised, controlled, phase II trial
title_full_unstemmed Afatinib in combination with GEMOX chemotherapy as the adjuvant treatment in patients with ErbB pathway mutated, resectable gallbladder cancer: study protocol for a ctDNA-based, multicentre, open-label, randomised, controlled, phase II trial
title_short Afatinib in combination with GEMOX chemotherapy as the adjuvant treatment in patients with ErbB pathway mutated, resectable gallbladder cancer: study protocol for a ctDNA-based, multicentre, open-label, randomised, controlled, phase II trial
title_sort afatinib in combination with gemox chemotherapy as the adjuvant treatment in patients with erbb pathway mutated, resectable gallbladder cancer: study protocol for a ctdna-based, multicentre, open-label, randomised, controlled, phase ii trial
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9980349/
https://www.ncbi.nlm.nih.gov/pubmed/36854604
http://dx.doi.org/10.1136/bmjopen-2022-061892
work_keys_str_mv AT yangmao afatinibincombinationwithgemoxchemotherapyastheadjuvanttreatmentinpatientswitherbbpathwaymutatedresectablegallbladdercancerstudyprotocolforactdnabasedmulticentreopenlabelrandomisedcontrolledphaseiitrial
AT zhaoyuhao afatinibincombinationwithgemoxchemotherapyastheadjuvanttreatmentinpatientswitherbbpathwaymutatedresectablegallbladdercancerstudyprotocolforactdnabasedmulticentreopenlabelrandomisedcontrolledphaseiitrial
AT liyongsheng afatinibincombinationwithgemoxchemotherapyastheadjuvanttreatmentinpatientswitherbbpathwaymutatedresectablegallbladdercancerstudyprotocolforactdnabasedmulticentreopenlabelrandomisedcontrolledphaseiitrial
AT cuixuya afatinibincombinationwithgemoxchemotherapyastheadjuvanttreatmentinpatientswitherbbpathwaymutatedresectablegallbladdercancerstudyprotocolforactdnabasedmulticentreopenlabelrandomisedcontrolledphaseiitrial
AT liufatao afatinibincombinationwithgemoxchemotherapyastheadjuvanttreatmentinpatientswitherbbpathwaymutatedresectablegallbladdercancerstudyprotocolforactdnabasedmulticentreopenlabelrandomisedcontrolledphaseiitrial
AT wuwenguang afatinibincombinationwithgemoxchemotherapyastheadjuvanttreatmentinpatientswitherbbpathwaymutatedresectablegallbladdercancerstudyprotocolforactdnabasedmulticentreopenlabelrandomisedcontrolledphaseiitrial
AT wangxuan afatinibincombinationwithgemoxchemotherapyastheadjuvanttreatmentinpatientswitherbbpathwaymutatedresectablegallbladdercancerstudyprotocolforactdnabasedmulticentreopenlabelrandomisedcontrolledphaseiitrial
AT limaolan afatinibincombinationwithgemoxchemotherapyastheadjuvanttreatmentinpatientswitherbbpathwaymutatedresectablegallbladdercancerstudyprotocolforactdnabasedmulticentreopenlabelrandomisedcontrolledphaseiitrial
AT liuyun afatinibincombinationwithgemoxchemotherapyastheadjuvanttreatmentinpatientswitherbbpathwaymutatedresectablegallbladdercancerstudyprotocolforactdnabasedmulticentreopenlabelrandomisedcontrolledphaseiitrial
AT liuyingbin afatinibincombinationwithgemoxchemotherapyastheadjuvanttreatmentinpatientswitherbbpathwaymutatedresectablegallbladdercancerstudyprotocolforactdnabasedmulticentreopenlabelrandomisedcontrolledphaseiitrial